Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

4 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 4

3(75.0%)

Phase 3

1(25.0%)

4Total

Phase 4(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT04826562Phase 4Unknown

Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)

Role: lead

NCT02858050Completed

Portal-724 MEMS for Medication Adherence Patients Taking HCV Medications

Role: lead

NCT02220868Phase 4Completed

Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study

Role: lead

NCT01609569Unknown

Pro-calcitonin Marker as Indicator of Ischemia in Patients With Complicated Coronary Intervention.

Role: lead

NCT00752037Phase 4Completed

Safety Study of Lopinavir/Ritonavir With Raltegravir in HIV-infected Patients

Role: lead

NCT00285883Phase 3Completed

Directly Observed Therapy in High Risk Populations in Newark, NJ

Role: lead

All 6 trials loaded